Linked Life Data

15732092

Source:http://linkedlifedata.com/resource/pubmed/id/15732092

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15732092rdf:typepubmed:Citationlld:pubmed
pubmed-article:15732092lifeskim:mentionsumls-concept:C0019196lld:lifeskim
pubmed-article:15732092lifeskim:mentionsumls-concept:C0003451lld:lifeskim
pubmed-article:15732092lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:15732092lifeskim:mentionsumls-concept:C0033607lld:lifeskim
pubmed-article:15732092lifeskim:mentionsumls-concept:C0017431lld:lifeskim
pubmed-article:15732092lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:15732092lifeskim:mentionsumls-concept:C1313841lld:lifeskim
pubmed-article:15732092pubmed:issue4lld:pubmed
pubmed-article:15732092pubmed:dateCreated2005-4-5lld:pubmed
pubmed-article:15732092pubmed:abstractTextBILN-2061, a specific and potent peptidomimetic inhibitor of the HCV NS3 protease, has recently been shown to markedly lower serum hepatitis C virus (HCV)-RNA levels in patients chronically infected with HCV genotype 1 in three 2-day proof of principle studies. The aim of the current study was to assess the antiviral efficacy of BILN-2061 in patients with genotypes 2 and 3 HCV infection. The antiviral efficacy, pharmacokinetics, and tolerability of 500 mg twice-daily BILN-2061 given as monotherapy for 2 days in 10 patients chronically infected with non-genotype 1 HCV (genotype 2: n = 3; genotype 3: n =7) and minimal liver fibrosis (Ishak score 0-2) were assessed in a placebo-controlled (placebo n = 2), double-blind pilot study. HCV-RNA levels decreased by > or =1 log(10) copies/mL in 4 of 8 patients treated with BILN-2061. One patient showed a weak response of <1 log(10) copies/mL. Three of 8 treated patients showed no response. There was no correlation between baseline viral concentration or genotype and response. BILN-2061 exhibited good systemic exposure after oral administration and was well tolerated. In conclusion, the antiviral efficacy of the HCV serine protease inhibitor BILN-2061 is less pronounced and more variable in patients with HCV genotype 2 or 3 infection compared with previous results in patients with HCV genotype 1. A lower affinity of BILN-2061 for the NS3 protease of genotypes 2 and 3 HCV is most likely a major contributor to these findings.lld:pubmed
pubmed-article:15732092pubmed:languageenglld:pubmed
pubmed-article:15732092pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15732092pubmed:citationSubsetIMlld:pubmed
pubmed-article:15732092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15732092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15732092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15732092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15732092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15732092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15732092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15732092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15732092pubmed:statusMEDLINElld:pubmed
pubmed-article:15732092pubmed:monthAprlld:pubmed
pubmed-article:15732092pubmed:issn0270-9139lld:pubmed
pubmed-article:15732092pubmed:authorpubmed-author:HinrichsenHol...lld:pubmed
pubmed-article:15732092pubmed:authorpubmed-author:WedemeyerHein...lld:pubmed
pubmed-article:15732092pubmed:authorpubmed-author:YongChan-LoiC...lld:pubmed
pubmed-article:15732092pubmed:authorpubmed-author:BenhamouYvesYlld:pubmed
pubmed-article:15732092pubmed:authorpubmed-author:ReiserMarkusMlld:pubmed
pubmed-article:15732092pubmed:authorpubmed-author:ReesinkHenk...lld:pubmed
pubmed-article:15732092pubmed:authorpubmed-author:NehmizGerhard...lld:pubmed
pubmed-article:15732092pubmed:authorpubmed-author:SteinmannGerh...lld:pubmed
pubmed-article:15732092pubmed:authorpubmed-author:AvendanoCrist...lld:pubmed
pubmed-article:15732092pubmed:authorpubmed-author:RibaNeusNlld:pubmed
pubmed-article:15732092pubmed:issnTypePrintlld:pubmed
pubmed-article:15732092pubmed:volume41lld:pubmed
pubmed-article:15732092pubmed:ownerNLMlld:pubmed
pubmed-article:15732092pubmed:authorsCompleteYlld:pubmed
pubmed-article:15732092pubmed:pagination832-5lld:pubmed
pubmed-article:15732092pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:meshHeadingpubmed-meshheading:15732092...lld:pubmed
pubmed-article:15732092pubmed:year2005lld:pubmed
pubmed-article:15732092pubmed:articleTitleAntiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.lld:pubmed
pubmed-article:15732092pubmed:affiliationRuhr-Universität Bochum, Bochum, Germany. markus.reiser@rub.delld:pubmed
pubmed-article:15732092pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15732092pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:15732092pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:15732092pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:15732092pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15732092lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15732092lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15732092lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15732092lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15732092lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15732092lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15732092lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15732092lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15732092lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15732092lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15732092lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15732092lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15732092lld:pubmed